Further Information
Chromogranin-A, CgA, Pituitary secretory protein I, SP-I, Vasostatin-1, Vasostatin I, Vasostatin-2, Vasostatin II, EA-92, ES-43, Pancreastatin, SS-18, WA-8, WE-14, LF-19, AL-11, GV-19, GR-44, ER-37, CHGA
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE): 0.25-0.5 ug/ml for 30 min at RT
Prediluted IHC only format: incubate for 30 min at RT (1)
Optimal dilution of the recombinant Chromogranin A antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Chromogranin A is present in neuroendocrine cells throughout the body, including the neuroendocrine cells of the large and small intestine, adrenal medulla and pancreatic islets. It is an excellent marker for carcinoid tumors, pheochromocytomas, paragangliomas, and other neuroendocrine tumors. Co-expression of chromogranin A and neuron specific enolase (NSE) is common in neuroendocrine neoplasms. Reportedly, co-expression of certain keratins and chromogranin indicates neuroendocrine lineage. The presence of strong anti-chromogranin staining and absence of anti-keratin staining should raise the possibility of paraganglioma. The co-expression of chromogranin and NSE is typical of neuroendocrine neoplasms. Most pituitary adenomas and prolactinomas readily express chromogranin.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant human protein was used as the immunogen for the recombinant Chromogranin A antibody.
1113
chromogranin A (parathyroid secretory protein 1)
CHGA
Homo sapiens
Liquid
Protein A affinity chromatography
Cancer,Neuroscience,Signal Transduction
Does not react with rat
P10645
Optimal dilutions for each application to be determined by the researcher